The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adaptimmune Therapeutics plc Common 00653A107   5,815,569 6,287,101 SH   SOLE   6,287,101 0 0
Dyne Therapeutics, Inc. Common 26818M108   55,702,159 4,951,303 SH   SOLE   4,951,303 0 0
Entrada Therapeutics, Inc. Common 29384C108   67,006,370 4,425,784 SH   SOLE   4,425,784 0 0
Harpoon Therapeutics, Inc. Common 41358P106   2,223,285 3,131,388 SH   SOLE   3,131,388 0 0
iTeos Therapeutics, Inc. Common 46565G104   36,261,513 2,738,785 SH   SOLE   2,738,785 0 0
Oncorus, Inc. Common 68236R103   115,403 2,849,464 SH   SOLE   2,849,464 0 0
Repare Therapeutics, Inc. Common 760273102   23,727,089 2,242,636 SH   SOLE   2,242,636 0 0
Werewolf Therapeutics, Inc. Common 95075A107   13,066,725 4,284,172 SH   SOLE   4,284,172 0 0